BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Han JW, Yang H, Lee HL, Bae SH, Choi JY, Lee JW, Kim HJ, Lee S, Cho SG, Min CK, Kim DW, Yoon SK. Risk factors and outcomes of hepatitis B virus reactivation in hepatitis B surface antigen negative patients with hematological malignancies. Hepatol Res 2016;46:657-68. [PMID: 26445232 DOI: 10.1111/hepr.12603] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Lee HL, Jang JW, Han JW, Lee SW, Bae SH, Choi JY, Han NI, Yoon SK, Kim HJ, Lee S, Cho SG, Min CK, Kim DW, Lee JW. Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B. Dig Dis Sci 2019;64:2992-3000. [PMID: 30982209 DOI: 10.1007/s10620-019-05614-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
2 Tsukune Y, Sasaki M, Odajima T, Isoda A, Matsumoto M, Koike M, Tamura H, Moriya K, Ito S, Asahi M, Imai Y, Tanaka J, Handa H, Koiso H, Tanosaki S, Hua J, Hagihara M, Yahata Y, Suzuki S, Watanabe S, Sugimori H, Komatsu N. Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents' era. Ann Hematol 2016;95:1465-72. [PMID: 27358178 DOI: 10.1007/s00277-016-2742-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
3 Park H, Kim DY, Kim SJ, Chung H, Cho H, Jang JE, Cheong JW, Min YH, Song JW, Kim JS. HBsAg-Negative, Anti-HBc-Negative Patients Still Have a Risk of Hepatitis B Virus-Related Hepatitis after Autologous Stem Cell Transplantation for Multiple Myeloma or Malignant Lymphoma. Cancer Res Treat 2018;50:1121-9. [PMID: 29198097 DOI: 10.4143/crt.2017.329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
4 Pattullo V. Prevention of Hepatitis B reactivation in the setting of immunosuppression. Clin Mol Hepatol. 2016;22:219-237. [PMID: 27291888 DOI: 10.3350/cmh.2016.0024] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 9.3] [Reference Citation Analysis]
5 Matsubara T, Nishida T, Shimoda A, Shimakoshi H, Amano T, Sugimoto A, Takahashi K, Mukai K, Yamamoto M, Hayashi S, Nakajima S, Fukui K, Inada M. The combination of anti-HBc and anti-HBs levels is a useful predictor of the development of chemotherapy-induced reactivation in lymphoma patients with resolved HBV infection. Oncol Lett. 2017;14:6543-6552. [PMID: 29151907 DOI: 10.3892/ol.2017.7012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
6 Chen QY, Wang XY, Harrison TJ, He X, Hu LP, Li KW, Jia HH, Yang QL, Wang C, Fang ZL. HBsAg may reappear following reactivation in individuals with spontaneous HBsAg seroclearance 8 years previously. Epidemiol Infect 2017;145:728-38. [PMID: 27917751 DOI: 10.1017/S095026881600279X] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
7 Marrone A, Capoluongo N, D'Amore C, Pisaturo M, Esposito M, Guastafierro S, Siniscalchi I, Macera M, Boemio A, Onorato L, Rinaldi L, Minichini C, Adinolfi LE, Sagnelli E, Mastrullo L, Coppola N. Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy. J Viral Hepat. 2018;25:198-204. [PMID: 29029365 DOI: 10.1111/jvh.12802] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
8 Zhang Z, Zhang Y, Xu N, Huang C, Li X, Li J. High risk of occult hepatitis B virus infection in leukemia patients from China. Arch Virol 2017;162:349-57. [PMID: 27743257 DOI: 10.1007/s00705-016-3111-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
9 Doi A, Sakamori R, Tahata Y, Urabe A, Morishita N, Yamada R, Furuta K, Kodama T, Hikita H, Yakushijin T. Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: Analysis of a Japanese prospective cohort. Hepatol Res. 2017;47:1438-1444. [PMID: 28585404 DOI: 10.1111/hepr.12919] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
10 Talaat N, Tillmann HL. Injury pattern recognition to discriminate competing causes of liver injury. Liver Int 2019;39:821-5. [PMID: 30703293 DOI: 10.1111/liv.14056] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
11 Tsukune Y, Sasaki M, Komatsu N. Reactivation of Hepatitis B Virus in Patients with Multiple Myeloma. Cancers (Basel) 2019;11:E1819. [PMID: 31752356 DOI: 10.3390/cancers11111819] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
12 Koffas A, Dolman GE, Kennedy PT. Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians. Clin Med (Lond). 2018;18:212-218. [PMID: 29858430 DOI: 10.7861/clinmedicine.18-3-212] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]